In mid-January 2025, J.P. Morgan held its annual health care conference for biomedical investors. Widely covered in the financial press, the conference conveyed optimism, highlighting great investment opportunities in gene and cell therapies, artificial intelligence (AI)–powered digital health solutions, and medical robotics. Attendee Juergen Eckhardt, who leads Bayer’s impact investment unit, summarized: “It’s clear the […]
